baber/WOPTO huggingface dataset:
Patent NZ-532317-A (NZ)
Title: Substituted diphenyl heterocycles useful for treating hepatitis C virus (HCV) infection
Inventor: SINGH RAJINDER
IPC: C07D249/08
Filed: 2002-11-01
Abstract: Substituted diphenyl heterocycle compounds of formula (I) and pharmaceutical compositions thereof that inhibit replication of hepatitis C virus (HCV), and intermediate compounds useful in the synthesis of the compounds of formula (I) are disclosed, wherein the variables are as defined in the specification. These compounds of formula (I) and/or compositions thereof are suitable for inhibiting HCV replication and/or proliferation and treating or preventing HCV infections.
Patent NZ-535627-A (NZ)
Title: Ladder support
Inventor: DRURY DAVID LAURANCE
Filed: 2005-03-27
Abstract: A ladder support including; a support bracket adapted to engage with at least one support surface, and a prehensile connector adapted to engage with a single rung of a ladder, said connector defining a receiving cavity with a mouth and a main body, wherein the span of said mouth is less than the diameter of a rung to which the connector is to be engaged, said connector being formed from a resilient material.
Patent NZ-536791-A (NZ)
Title: Inplantable polymeric stent for vasovasostomy
Inventor: VRIJHOF HENRICUS JOSEPHUS ELIS
IPC: A61F2/06
Filed: 2003-04-25
Abstract: Disclosed herein is an implantable tubular medical device for vasovasostomy in mammals, wherein the device is made from a hydrophilic biocompatible polymer, the polymer comprising a hydrophilic component, preferably N-vinylpyrrolidone, a hydrophobic component, preferably N-butylmethacrylate and a cross-linker, preferably tetraethyleneglycol dimethacrylate, and wherein the molar ratio of the hydrophilic component and the hydrophobic component is from 0.1 to 10. A method for the preparation of the hydrophilic biocompatible polymer by polymerisation from its components is also disclosed. Vasovasostomy is a microsurgical operation for reversing the vasectomy if, for some reason, the male has the desire to become fertile again.
Patent NZ-538122-A (NZ)
Title: Laser apparatus and method for calibrating more than one laser source in different directions in space
Inventor: SERGYEYENKO OLEKSIY P
IPC: G01C5/00
Filed: 2005-02-08
Abstract: A laser calibration device is disclosed which includes; (a) a housing (22), (b) a pendulum (26) pivotally coupled to the housing (22) and suspending downwards therefrom, (c) a laser deck (28) mounted to the pendulum (26), (d) at least one laser (30) for emitting a laser line, where the laser (30) is pivotally mounted to the laser deck (28) and has a laser barrel which is rotatable within a barrel holder, and a laser lens pivotally coupled to the laser barrel, (e) a first adjustment mechanism mounted between the laser deck (28) and the laser for pivoting the laser with respect to the laser deck (28) to adjust a pitch of the laser line, (f) a second adjustment mechanism mounted between the barrel holder and the laser barrel to rotate the laser barrel with respect to the barrel holder to adjust a roll of the laser line, (g) a third adjustment mechanism mounted between the laser barrel and the laser lens to pivot the laser lens with respect to the laser barrel to adjust a crowning of the laser line, and (h) a fourth adjustment mechanism mounted to the pendulum (26) for adjusting a center of gravity of the pendulum (26), wherein the first, second, third, and fourth adjustment mechanisms are used to make horizontal the laser line emitted from the laser.
Patent NZ-544681-A (NZ)
Title: Sub-lingual administration of cannabis
Inventor: ROSS CALVIN
IPC: A61K47/26
Filed: 2001-03-09
Abstract: Disclosed is the use of cannabis in the preparation of an aerosol or spray pharmaceutical formulation, adapted for sub-lingual administration, for the therapeutic treatment of a patient. Also disclosed is a device for providing pharmaceutical doses comprising a container filled with the pharmaceutical formulation defined above and valve means arranged for delivering aerosol or spray doses of said pharmaceutical formulation to the exterior of the container.
Patent NZ-548308-A (NZ)
Title: Branched polymeric sugars and nucleotides thereof
Inventor: DEFREES SHAWN
IPC: C07H5/04
Filed: 2005-01-26
Abstract: Disclosed are modified sugars and nucleotide phosphates thereof, as represented by the general formulae (I) and (II), wherein R1 is H, CH2OR7, COOR7 or OR7; R7 represents H, optionally substituted alkyl or optionally substituted heteroalkyl; R2 is a member selected from H, OH, fluoro, chloro, bromo, a tosylate ester, a mesylate ester, a triflate ester; and a moiety that includes a nucleotide; R3, R4, R5, R6 and R6' are independently selected from H, optionally substituted alkyl, OR9, and NHC(O)R10, and at least one of R3, R4, R5, R6 and R6' includes a moiety having the formula: -NHC(O)(CH2)s-NHC(O)-R11, R11 being a polymeric modifying moiety; wherein R11 and the remaining substituents are as defined herein. Of particular importance are compounds where R2 represents cytidine monophosphate.
Patent NZ-561708-A (NZ)
Title: Dosage forms of risedronate
Inventor: DANSEREAU RICHARD JOHN
IPC: A61K9/32
Filed: 2005-11-23
Abstract: Disclosed is an oral dosage form having pharmaceutically effective absorption comprising: -from about 1 mg to about 250 mg of a bisphosphonate selected from the group consisting of risedronate and acids, salts, and esters thereof; -from about 10 mg to about 500 mg of EDTA or salts thereof; and -a delayed release mechanism to immediately release the risedronate and the EDTA in the small intestine; wherein said oral dosage form weighs no greater than 1 gram. Also disclosed is the use, in the manufacture of an oral dosage form having pharmaceutically effective absorption for treating a disease selected from the group consisting of osteoporosis, Paget's disease, hyperparathyroidism, hypercalcemia of malignancy, osteolytic bone metastasis, and combinations thereof, of: -from about 1 mg to about 250 mg of a bisphosphonate selected from the group consisting of risedronate and acids, salts, and esters thereof; -from about 10 mg to about 500 mg of EDTA or salts thereof; and -a delayed release mechanism to immediately release the risedronate and the EDTA in the small intestine; wherein said oral dosage form weighs no greater than 1 gram.
Patent NZ-563431-A (NZ)
Title: Device for quantitative analysis of a metabolite profile
Inventor: RAMSAY STEVEN LEWIS
IPC: G16B50/30
Filed: 2006-06-29
Abstract: Provided is an insert for a device for the quantitative mass spectrometric analysis of a metabolite profile of at least one metabolite selected from the group comprising amino acids, peptides, acylcarnitines, monosaccharides, lipids, phospholipids, prostaglandins, hydroxyeicosatetraenoic acids, hydroxyoctadecadienoic acids, steroids, and bile acids in a biological sample, wherein said insert comprises a porous support with at least one internal standard embedded therein, wherein said internal standard is a reference compound of known absolute amount selected from the group comprising amino acids, peptides, acylcarnitines, monosaccharides, lipids, phospholipids, prostaglandins, hydroxyeicosatetraenoic acids, hydroxyoctadecadienoic acids, steroids, and bile acids, and wherein the internal standard belongs to the same family of the metabolite(s) to be analyzed in the biological sample, and is labelled with isotopes.
Patent NZ-569321-A (NZ)
Title: Novel retinol derivatives as skin whitening / lightening agents, and cosmetic compositions containing them
Inventor: BORDAT PASCAL
IPC: A61K8/67
Filed: 2006-12-14
Abstract: Disclosed are retinol derivatives as represented by formula (I), wherein R1 represents R'1 or -A-R'-1, in which R'1 is chosen from among -COOH, -COOR3, -CONH2, -CONHR3, CONR3R4, -CHO, -CH2OH, -CH2OR5, and A represents a linear or branched alkylene group, linear or branched alkenylene group or linear or branched alkynylene group; R2 represents: an optionally substituted aryl or heteroaryl group, an osidic residue, a fatty acid residue, an -OC-(CH2)n-CO-tocopheryl group, or an -R'2-O-R6 group; wherein the other substituents are as defined herein; their enantiomers and diastereoisomers, as well as any salts resulting from addition to an acid or physiologically acceptable base. Also disclosed is a cosmetic or dermatological composition characterized in that it contains at least one of compound as defined above. Further disclosed is the use of at least one compound of formula (I) as defined above for the manufacture of a dermatological composition intended for use in depigmenting the skin and/or body hair and/or head hair.
Patent NZ-569942-A (NZ)
Title: Tumour vaccine comprising allogeneic or xenogeneic tumour cells and a lysate of a syngeneic tumor cell
Inventor: STATHOPOULOS APOSTOLOS
IPC: A61K35/30
Filed: 2007-01-26
Abstract: Disclosed is a composition for the treatment or prevention of a tumour in a patient, comprising (i) whole allogeneic or xenogeneic tumour cells; (ii) a lysate of a syngeneic tumour cell; and (iii) a pharmaceutically acceptable excipient, wherein the cells of (i) and (ii) are defined with reference to the cells of the patient's tumour. Also disclosed is the use of (i) whole allogeneic or xenogeneic tumour cells and (ii) a lysate of a syngeneic tumour cell, in the manufacture of a medicament for the treatment of a tumour in a patient.
Patent NZ-579644-A (NZ)
Title: Antibodies against erbb3 and uses thereof
Inventor: MURUGANANDAM ARUMUGAM
IPC: A61K33/243
Filed: 2008-02-15
Abstract: Disclosed are ErbB3 antibodies that inhibit ErbB3 signalling. The antibodies can be used in the treatment of cancer.
Patent NZ-579856-A (NZ)
Title: An improved implement mounting device
Inventor: VENN CHRISTOPHER GRAHAM
IPC: B60D1/54
Filed: 2009-09-21
Abstract: Disclosed is a mounting apparatus for mounting an implement to a vehicle which has two spaced apart rigid arms fixed rigidly to its front or rear. The mounting apparatus includes a movement transfer mechanism and a pair of extension members linked to the movement transfer mechanism. The extension members are configured to move when the movement transfer mechanism is operated. The mounting apparatus further includes a housing and a mounting means configured to attach an implement. Each extension member also includes a bracket which is configured to engage with at least one or more arms of the vehicle.
Patent NZ-581990-A (NZ)
Title: N-[2-(Thiazolo[5,4-b]pyridin-2-yl)-phenyl]-3-phenyl-benzamide derivatives
Inventor: BEMIS JEAN
IPC: A61K31/426
Filed: 2008-06-20
Abstract: Disclosed are N-[2-(thiazolo[5,4-b]pyridin-2-yl)-phenyl]-3-phenyl-benzamide derivatives as represented by the general formula (II) or a salt thereof, wherein: X1 to X4 are CH; R2 is phenyl; and R1 is a solubilizing group such as a piperazin-1-yl, 4-(methoxyethyl)-piperazin-1-yl, 3,5-dimethylpiperazin-1-yl, morpholin-4-yl, piperidin-1-yl, 4-aminopiperidin-1-yl, pyrrolidin-1-yl, 3-fluoropyrrolidin-1-yl, -NH-(pyrrolidin-3-yl), 1,4-diazabicyclo[2.2.1]heptan-1-yl, morpholin-4-ylmethyl, piperazin-1-ylmethyl or a pyrrolidin-1-ylmethyl group. Representarive compounds include N-[2-(6-(morpholin-4-ylmethyl)-thiazolo[5,4-b]pyridin-2-yl)-phenyl]-3-phenyl-benzamide, N-[2-(6-(piperazin-1-ylmethyl)-thiazolo[5,4-b]pyridin-2-yl)-phenyl]-3-phenyl-benzamide and N-[2-(6-(pyrrolidin-1-ylmethyl)-thiazolo[5,4-b]pyridin-2-yl)-phenyl]-3-phenyl-benzamide. Further disclosed is a pharmaceutical composition which comprises a compound as defined above and a pharmaceutically acceptable carrier for treating a subject suffering from or susceptible to insulin resistance, a metabolic syndrome, diabetes, or complications thereof, or for increasing insulin sensitivity in a subject.
Patent NZ-583363-A (NZ)
Title: Movable railway track covering
Inventor: NEUMANN BERNHARD
IPC: E01C9/04
Filed: 2008-10-08
Abstract: Disclosed is a railway track covering which comprises a covering element (7) arranged at rail level between the rails (3) of the track and also comprises covering element (8) adjoining the rails on the outside. The covering elements (7, 8) are provided at their edges (10) facing the rails with supporting members (9) which are used to support these covering elements on the rails. The supporting members are mounted on said covering elements so as to be displaceable in the rail longitudinal direction. At least two supporting members are arranged displaceably on each edge of the covering elements that faces a rail of the track. Preferably, the supporting members are mounted so as to be displaceable in the rail longitudinal direction and so as to be pivotable about a geometric axis which is parallel to the direction of displacement.
Patent NZ-584542-A (NZ)
Title: Magnetic levitation vibration systems and methods for treating or preventing musculoskeletal indications using the same
Inventor: LEUNG KWOK-SUI
IPC: A61H1/00
Filed: 2008-09-19
Abstract: A magnetic levitation vibration system is disclosed. The magnetic levitation vibration system comprises: a top plate and a base plate, at least one first and second magnet, at least one electromagnetic actuator, a controller, a sensor, and a control circuit. The top plate and base plate have top and bottom surfaces where the base plate is located under the top plate and the top surface of the base plate faces the bottom surface of the top plate. The first magnet is fixed on the bottom surface of the top plate and the second magnet is fixed on the top surface of the base plate such that the magnets align. The first magnet, with an equivalent polarity faces the second magnet, which results in a repulsive force. The electromagnetic actuator comprises an upper half fixed on the bottom surface of the top plate and a lower half fixed on the top surface of the base plate and aligns with the upper half. The controller adjusts the frequency of vibration of the top plate. The sensor monitors magnitude of vibration of the top plate to generate monitored signals and a control circuit is electrically connected to the lower half of the actuator and configured to adjust magnitude of vibration of the top plate in response to the monitored signals.
Patent NZ-585051-A (NZ)
Title: 1,2,4,-triazin-3,5-dione compounds for treating disorders that respond to modulation of the dopamine d3 receptor
Inventor: HAUPT ANDREAS
IPC: A61K31/53
Filed: 2008-10-31
Abstract: Disclosed is a 1,2,4-triazin-3,5-dione compound, the physiologically tolerated salts, the tautomers and the N-oxides of formula I, wherein: A is a saturated or unsaturated hydrocarbon chain having a chain length of 4 to 6 carbon atoms, the hydrocarbon chain being unsubstituted or substituted by 1, 2 or 3 methyl groups; R1 is selected from the group consisting of hydrogen, C1-C3 alkyl and fluorinated C1-C3 alkyl; R2 is hydrogen, halogen, cyano, C1-C3 alkyl, C1-C3 alkoxy, fluorinated C1-C3 alkyl or fluorinated C1-C3 alkoxy; R3 is selected from the group consisting of branched C4-C6 alkyl and C3-C6 cycloalkyl, and R4 is C1-C3 alkyl, C3-C6 cycloalkyl, fluorinated C1-C3 alky and fluorinated C3-C6 cycloalkyl. An example of a compound of formula I is 2-{ 4-[4-(2-tert-Butyl-6-trifluoromethyl-pyrimidin-4-yl)-piperazin-l-yl]-butyl} -2H-[1 ,2,4]triazine-3,5-dione. Further disclosed is a pharmaceutical composition comprising at least one compound of formula I, and the use of a therapeutically effective amount of a compound of formula I for the manufacture of a medicament for the treatment of a medical disorder susceptible to treatment with a dopamine D3 receptor ligand, such as schizophrenia, bipolar disorder, drug addiction, diabetic nephropathy.
Patent NZ-586303-A (NZ)
Title: Antibody-containing formulation for the use for treating cardiovascular diseases associated with atherosclerosis
Inventor: NILSSON FREDRIK
IPC: A61K47/18
Filed: 2008-12-22
Abstract: An aqueous pharmaceutical composition comprising a therapeutically effective amount of an antibody having a heavy chain amino acid sequence of SEQ ID NO: 3 and a light chain amino acid sequence of SEQ ID NO: 4 and a pharmaceutically acceptable adjuvant, diluent, carrier or excipient, wherein said composition has a pH of 4 to 6.
Patent NZ-589306-A (NZ)
Title: Orally administrable dosage forms comprising angiogenin and uses thereof
Inventor: COCKS BENJAMIN
IPC: A61K35/12
Filed: 2009-05-14
Abstract: Provided is the use of angiogeninn the manufacture of a medicament for promoting development of a hemovascular network particularly following heart attack, promoting wound healing, providing a neuroprotective effect, treating neurodegenerative diseases, treating ALS, treating motor neuron disease, inhibiting replication of RNA viruses in primary activated T cells and chronically infected cells, treating RNA infection by Retroviridae, Cystoviridae, Birnaviridae, Reoviridae, Coronaviridae, Flaviviridae, Togaviridae, "Arterivirus", Astroviridae, Caliciviridae, Picornaviridae, Potyviridae, Orthomyxoviridae, Filoviridae, Paramyxoviridae, Rhabdoviridae, Arenaviridae, and Bunyaviridae, treating human immunodeficiency virus, increasing bone density, treating disorders of bone homeostasis, treating osteoporosis, especially in the elderly and/or postmenopausal women, treating glucocorticoid- induced osteoporosis, treating osteopenia, treating osteoarthritis, treating osteoporosis-related fractures, and treating low bone mass due to chronic glucocorticoid therapy, wherein the medicament is for administering orally and the angiogenin is provided in the absence of a carrier, excipient or encapsulation means intended to facilitate delivery of angiogenin to the bloodstream without substantial degradation in the gut.
Patent NZ-589933-A (NZ)
Title: Top gripping carrier with end supports which interlock with a single longitudinal partition having a handle portion
Inventor: TEIO NINA HAZEL
IPC: B65D71/52
Filed: 2010-12-14
Abstract: 589933 A container carrier having a base portion with a planar bottom. The carrier has opposing ends which depend upwardly and inwardly from the bottom to meet centrally above the bottom. An aperture is provided adjacent each end of the base portion whereby the apertures are substantially parallel with and spaced apart from the bottom. The carrier has a pair of support portions depending upwardly from opposing sides of the bottom of the base portion. The carrier also has a pair of handle portions depending upwardly in a facing relationship from respective opposing ends of the base portion. Opposing sides of each handle portion have a tab and respective tabs of each handle portion are engaged with a slot provided in the orthogonal support portions. The tabs extend along the length of the sides of the handle portions and are defined by channels extending inwardly from the sides of the handle portion at or adjacent a distal end thereof.
Patent NZ-591163-A (NZ)
Title: Method for testing substances or substance mixtures and the use thereof
Inventor: PLATSCH HERBERT
IPC: G01N33/68
Filed: 2009-09-04
Abstract: Disclosed is a method for testing a substance or a substance mixture and the use thereof for identifying and/or characterizing the mode of action of the substance or the substance mixture or for determining the biochemical and/or metabolic state of an organism or group of organisms or part(s) thereof after exposure to the substance or the substance mixture.
Patent NZ-596269-A (NZ)
Title: Protease screening methods and proteases identified thereby
Inventor: MADISON EDWIN L
IPC: C12N9/50
Filed: 2007-07-05
Abstract: Provided is a modified matrix type serine protease I (MT-SP1) polypeptide or a catalytically active portion thereof, comprising an amino acid replacement in a position corresponding to a position selected from among positions 23, 52, 60(g), 65, 71, 93, 95, 126, 129, 131, 136, 143, 144, 154, 164, 166, 184(a), 201, 209, 230, 234, and 244 , based on chymotrypsin numbering, whereby substrate specificity or activity is altered compared to the MT-SP1 polypeptide not containing the amino acid replacement(s). The peptide can be used to treat diseases mediated by compliment protein C2.
Patent NZ-597168-A (NZ)
Title: Dual variable domain immunoglobin and uses thereof
Inventor: WU CHENGBIN
IPC: A61K31/192
Filed: 2006-08-18
Abstract: 597168 DUAL VARIABLE DOMAIN IMMUNOGLOBIN AND USES THEREOF Provided is a binding protein comprising first and second polypeptide chains, wherein said first polypeptide chain comprises VD1-(X1)n-VD2-C-(X2)n, wherein VD1 is a first immunoglobulin heavy chain variable domain, VD2 is a second immunoglobulin heavy chain variable domain, C is an immunoglobulin constant domain, X1 is a linker with the proviso that it is not an immunoglobulin constant domain, and X2 is an Fc region; and said second polypeptide chain comprises VD1-(X1)n-VD2-C-(X2)n, wherein VD1 is a first immunoglobulin light chain variable domain, VD2 is a second immunoglobulin light chain variable domain, C is an immunoglobulin constant domain, X1 is a linker with the proviso that it is not an immunoglobulin constant domain, and X2 is an Fc region; wherein n is 0 or 1; and wherein the first and second polypeptide chains form two functional antigen binding sites.
Patent NZ-599191-A (NZ)
Title: Multi-granular feedback reporting and feedback processing for precoding in telecommunications
Inventor: JONGREN GEORGE
IPC: H04L1/00
Filed: 2010-09-30
Abstract: 599191 A method of operating a first device for reporting feedback information to a second device to assist the second device in precoding information which is carried over a multiple input, multiple output (MIMO) channel to the first device and the first device are disclosed. The first device is arranged to report feedback information to a second device using a multi-part feedback signal representing a multi-part matrix structure which is related to channel state information for a multiple-input, multiple output (MIMO) channel. The first device is arranged to transmit at least two different parts of the multi-part feedback signal to the second device with two respective different transmission granularities in time and/or frequency. The different parts of the multi-part feedback signal correspond to different constituent matrices of the multi-part matrix structure and the multi-part matrix structure comprises a precoder matrix structure. The precoder is derived from the channel state information and the feedback signal comprises a Kronecker product of two matrices comprising the multi-part matrix structure and the precoder matrix structure comprises a polarization matrix and a beamforming vector A method of operating a communications network comprising a first device and a second device and the communications network are also disclosed. The communication network comprises the above described first device and a second device. The second device is configured to use the feedback information to affect precoding of further information transmitted over the channel to the first device.
Patent NZ-600299-A (NZ)
Title: A laminated floor covering
Inventor: KHAN ZULFIQAR ANWAR
IPC: A47G27/02
Filed: 2010-12-02
Abstract: 600299 Disclosed is a floor covering including a primary backing layer having a fibrous face and an underside, wherein the fibrous face is formed from a bulked continuous filament yarn comprising a plurality of continuous filaments formed from a multi-component fibre comprising a biobased polyhexamethylene sebacamide polymer or a blend of a biobased polyhexamethylene sebacamide polymer together with up to 80wt% of at least one other polymer compatible with the biobased polyhexamethylene sebacamide polymer. Also disclosed is a method of making a floor covering comprising tufting or implanting a bulked continuous filament yarn into a primary backing material, wherein the yarn comprises a plurality of continuous filaments formed from a biobased polyhexamethylene sebacamide polymer or a blend of a biobased polyhexamethylene sebacamide polymer together with up to 80wt% of at least one other polymer compatible with the biobased polyhexamethylene sebacamide polymer.